HSHaihui Sheng

Haihui Sheng

*This is an algorithmically generated author record based on publicly available information.

Haihui Sheng has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma

    by Fuxing Liu, Donglan Yuan, Xia Liu, Shichao Zhuo, Xinyun Liu, Haihui Sheng, Min Sha, Jun Ye, Hong Yu

    Background: It is of great concern to identify prognostic signatures for the prediction and prediction of esophageal squamous cell carcinoma (ESCC), which is the lethal pathological type of malignancy. Method: Bulk RNA sequencing and scRNA-seq data were retrieved from GSE53624, GSE53622, and GSE188900. Disulfidptosis-related differentially expressed genes (DEGs) were identified between disulfidptosis-high score and disulfidptosis-low score groups. Functional annotation of DEGs were analyzed by Gene Ontology (GO). Consistent clustering and co-expression modules were analyzed, and then constructed a risk score model via multivariate Cox regression analysis. Immune infiltration and immunotherapy response analyses were conducted based on risk score. qRT-PCR, colony formation assay, and flow cytometry analysis were conducted in KYSE-150 and TE-1 cell lines. Results: Seven genes (CD96, CXCL13, IL2RG, LY96, TPK1, ACAP1, and SOX17) were selected as marker genes. CD96 and SOX17 are independent prognostic signatures for ESCC patients, with a significant correlation with infiltrated immune cells. ESCC patients had worse response to nivolumab in the high-risk group. Through cellular experiments, we found that CD96 expression was associated with apoptosis and cell cycle ESCC cells. Conclusion: In a word, the risk score based on disulfidptosis is associated with prognosis and the immune microenvironment, which may direct immunotherapy of ESCC. The key gene of risk score, namely CD96, plays a role in proliferation and apoptosis in ESCC. We offer an insight into the exploration of the genomic etiology of ESCC for its clinical management.


    • 1 August 2017
      • Vol. 10  (8) , 8795-8803

    Utility of genetic variants to predict prognosis in coronary artery disease patients receiving statin treatment.

    by Li Zhu, Xiaoli Ji, Lin Jiang, Yabin Zhu, Yumin Xu, Qinxiao Jiang, Jingjing Bao, Jun Ye, Haihui Sheng, Hong Yu

    Statins are widely used drugs for lowering low-density lipoprotein cholesterol (LDL-C) and can prevent cardiovascular events. This study aimed to evaluate the influence of single nucleotide polymorphisms (SNPs) and their cumulative effects on the prognosis of coronary artery disease (CAD) patients treated with statins. Sixteen SNPs were genotyped in 785 CAD patients receiving statin therapy, and their associations with clinical features and prognosis of patients were investigated. Four SNPs (rs2296651, rs11206510, rs8192870, and rs1801133) were significantly associated with complications of CAD (P<0.05). Four SNPs (rs8192870, rs4149056, rs12916, and rs2231142) affected blood lipid levels (P<0.05). Furthermore, rs1801133 showed a weak but significant association with fasting plasma glucose (P = 0.033). Survival analyses showed that rs11206510 (adjusted HR = 1.891, 95% CI: 1.188-3.010, P = 0.007) and rs1801133 (adjusted HR = 1.499, 95% CI: 1.141-1.971, P = 0.004) were independently associated with an increased risk of major cardiovascular events, and exhibited cumulative effect on even-free survival (adjusted HR = 1.810, 95% CI: 1.179-2.802, P = 0.007). In conclusion, rs11206510 and rs1801133 were independent risk factors for clinical outcome in CAD patients treated with statins.


  • UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy

    by Ling Zhang, Xili Cao, Liqian Zhang, Xuelin Zhang, Haihui Sheng, Kun Tao

    Purpose Urothelial carcinoma associated 1 (UCA1) functions as an oncogene, which promotes cancer cell proliferation, invasion, and metastasis, and is responsible for drug resistance. This study aimed to determine the expression level of UCA1 in ovarian cancer and to further investigate its clinical significance. Methods The expression levels of UCA1 in ovarian cancer and normal ovaries were determined by quantitative real-time PCR. The relationship between UCA1 expression and clinical features and the prognostic value of UCA1 for overall survival were examined. Results UCA1 expression in ovarian cancer tissues was significantly upregulated compared with normal ovarian tissues. High UCA1 expression was related to lymph node metastasis, FIGO stage, and response to chemotherapy. Kaplan–Meier analysis demonstrated that high UCA1 expression was associated with poorer overall survival in patients with ovarian cancer. Cox proportional hazards analysis showed that high UCA1 expression was an independent prognostic marker of poor outcome. This effect remained significant in the further stratification analysis. Conclusions Our findings provided the first evidence that UCA1 may serve as an indicator of response to chemotherapy and prognosis of ovarian cancer. UCA1 may play an important role in the progression of ovarian cancer.


    • 15 October 2015
      • Vol. 8  (10) , 18917-26

    Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

    by Yuanyuan Dong, Huasheng Xiao, Qi Wang, Chunxiu Zhang, Xiuming Liu, Na Yao, Haihui Sheng, Haiyan Li

    The cytochrome P450 enzymes play a critical role in the metabolism of many commonly prescribed drugs. Among them, the most important enzymes are highly polymorphic CYP2C9, CYP2C19, CYP2D6 and CYP3A5, which are responsible for about 40% of the metabolism of clinical used drugs. Here we developed a novel CYP450 oligonucleotide microarray that allow for detection of 32 known variations of CYP genes from a single multiplex reaction, including 19 polymorphisms of CYP2D6 gene, 8 polymorphisms of CYP2C9 gene, 4 polymorphisms of CYP2C19 gene and 1 polymorphism of CYP3A5 gene. 229 genomic DNA samples from unrelated Han subjects were analyzed. The microarray results showed to have high call rate and accuracy according to concordance with genotypes identified by independent bidirectional sequencing. Furthermore, we found that the major CYP2C9, CYP2C19, CYP2D6 and CYP3A5 alleles in Chinese Han population were CYP2C9*3 (allelic frequency of 10.7%), CYP2C9*2 (20.31%), CYP2C19*2 (5.68%), CYP2D6*10 (58.52%), CYP2D6*2 (13.76) and CYP3A5*3 (70.69%). With flexible DNA preparation, the microarray can significantly facilitates the process of detecting genetics variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 gene and provide safe and effective therapy for individual patients.


    • 19 November 2014
      • Vol. 4  (6) , 934-42

    Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors.

    by Yunhua Xu, Qunxiong Pan, Chongren Wang, Chunya He, Zijian Su, Xiaowei Guo, Jian Zhang, Min Kong, Shaoying Ke, Jianhua Zhang, et al.

    Many types of cancer have high antioxidant capacity that effectively scavenges reactive oxygen species and thus protect cancer cells against oxidative damage. The aim of this study was to examine the effect of 20 single nucleotide polymorphisms (SNPs) in 20 oxidative stress-related genes on clinical outcome in 219 patients with advanced non-small cell lung cancer (NSCLC) who were treated with EGFR tyrosine kinase inhibitors (TKIs). We assessed the associations of SNPs with prognosis in all patients as well as stratified by clinical characteristics. Three SNP (rs1695, rs2333227 and rs699512) were significantly associated with overall survival (OS). In a multivariate analysis, rs1695 AA and rs2333227 AG/GG genotypes were identified as independent prognostic factors for poor OS. Stratification analyses revealed that these 3 SNPs remained significantly associated with OS. Furthermore, there was a strong gene-dosage effect of these 3 SNPs on OS that patients with increasing number of unfavorable genotypes had significantly increased death risk. In conclusion, our findings provide the first evidence that genetic variants in oxidative stress-related genes may influence treatment outcome in advanced NSCLC patients receiving EGFR TKIs.


    • 4 March 2014
      • Vol. 94  (8) , 561-2

    [Mutation detection could guide the eradication treatment of antibiotic-resistant patients with Helicobacter pylori].

    by Hengjun Gao, Bensong Duan, Haihui Sheng

    • 6 April 2012
      • Vol. 5  (2) , 186-94

    ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese.

    by Haina Chai, Jie Pan, Xuelin Zhang, Xiaoyan Zhang, Xiaoying Shen, Hang Li, Kehao Zhang, Changqing Yang, Haihui Sheng, Hengjun Gao

    Genetic variations influence treatment outcomes in cancer patients treated with chemotherapy. Detection of pharmacogenetic markers associated with treatment response may enable doctor to plan more precise and effective treatment tailoring to individual cancer patients. A novel oligonucleotide microarray was developed to genotype 13 variations (DPYD*2, DPYD*5, DPYD*9, TYMS 6 bp Ins/Del, UGT1A1*6, UGT1A1*27, UGT1A1*28, GSTP1 Ile105Val, XRCC1 Arg399Gln, MTHFR C677T, MDR1 C3435T/A, MDR1 G2677A/T and ERCC1 C118T). The accuracy of genotypes obtained by microarray was assessed by independent sequencing. 73 patients first diagnosed with colorectal cancer (CRC) were treated with FOLFOX4 chemotherapy. All genotypes were successfully called by microarray, and were consistent with those identified by independent sequencing except two TYMS 6 bp Ins/Del genotypes. Patients with CT or TT genotype exhibited a higher probability of response to treatment than those with CC genotype. No other SNP was found to be associated with treatment response. Furthermore, these SNPs showed no associations with gastrointestinal, hematological or neurological toxicity. ERCC1 C118T may be a predictive marker of treatment response to 5-FU/platinum chemotherapy for CRC. The microarray can significantly facilitate the process of detecting genetic variations and may help doctor plan more effective medication for individual cancer patient.